BioAlliance Pharma accelerates its international clinical research program

Paris, November 28 2007 - BioAlliance Pharma SA (Euronext Paris - ticker code BIO) today announced it has extended its ongoing acyclovir Lauriad® Phase III trial in the treatment of oral herpes to the United States. Ten clinical centers have been opened in the country and will join the forty or so in Australia and Europe already participating in the trial, with a target of 640 patients.